3 Asian Growth Companies With High Insider Ownership Growing Earnings Up To 139%

As global markets experience a rally, buoyed by easing geopolitical tensions and new trade agreements, Asia's financial landscape is also witnessing significant developments. In this environment, growth companies with high insider ownership are particularly noteworthy as they often align management interests with shareholder value, providing potential resilience and strong earnings performance even amidst broader economic challenges.

Top 10 Growth Companies With High Insider Ownership In Asia

Name	Insider Ownership	Earnings Growth
Zhejiang Leapmotor Technology (SEHK:9863)	15.6%	60.5%
Vuno (KOSDAQ:A338220)	15.6%	109.8%
Techwing (KOSDAQ:A089030)	18.8%	68%
Suzhou Sunmun Technology (SZSE:300522)	35.4%	77.7%
Sineng ElectricLtd (SZSE:300827)	36%	26.9%
Samyang Foods (KOSE:A003230)	11.7%	24.8%
Oscotec (KOSDAQ:A039200)	21.1%	94.4%
M31 Technology (TPEX:6643)	30.8%	63.4%
Laopu Gold (SEHK:6181)	35.5%	41.2%
Fulin Precision (SZSE:300432)	13.6%	43.7%

Click here to see the full list of 604 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

Beijing Hotgen Biotech (SHSE:688068)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Beijing Hotgen Biotech Co., Ltd. specializes in the research, development, manufacture, and sale of in-vitro diagnostic products for medical and public safety inspections within the biomedicine field, with a market cap of approximately CN¥13.03 billion.

Operations: The company's revenue primarily comes from its in-vitro diagnostic products, totaling CN¥488.02 million.

Insider Ownership: 32.2%

Earnings Growth Forecast: 139% p.a.

Beijing Hotgen Biotech is poised for significant growth, with earnings expected to increase by 139.01% annually and revenue projected to grow at 26.3% per year, surpassing the Chinese market average. Despite this potential, recent financials revealed a net loss of CNY 24.01 million in Q1 2025, highlighting volatility and challenges ahead. While insider trading data for the past three months is unavailable, these factors underscore both opportunities and risks associated with high insider ownership dynamics.

• Take a closer look at Beijing Hotgen Biotech's potential here in our earnings growth report.
• Our valuation report unveils the possibility Beijing Hotgen Biotech's shares may be trading at a premium.

Suning.com (SZSE:002024)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Suning.com Co., Ltd. operates in the retail sector in China with a market cap of CN¥18.04 billion.

Operations: Suning.com Co., Ltd. generates revenue through its retail operations in China.

Insider Ownership: 20.1%

Earnings Growth Forecast: 29.1% p.a.

Suning.com shows potential for growth, with earnings forecasted to rise by 29.1% annually, outpacing the Chinese market average. The company recently turned profitable, reporting a net income of CNY 17.96 million in Q1 2025 compared to a prior loss. Despite trading significantly below estimated fair value and expanding its business scope, challenges remain as debt is not well covered by operating cash flow and Return on Equity projections are modest at 12.8%.

• Click to explore a detailed breakdown of our findings in Suning.com's earnings growth report.
• Our expertly prepared valuation report Suning.com implies its share price may be lower than expected.

Lepu Medical Technology (Beijing) (SZSE:300003)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lepu Medical Technology (Beijing) Co., Ltd. operates in the medical device and healthcare industry, focusing on developing and manufacturing cardiovascular devices, with a market cap of CN¥28.44 billion.

Operations: Lepu Medical Technology focuses on developing and manufacturing cardiovascular devices within the medical device and healthcare industry.

Insider Ownership: 13.1%

Earnings Growth Forecast: 42.6% p.a.

Lepu Medical Technology (Beijing) is poised for substantial earnings growth, with forecasts indicating a 42.6% annual increase, surpassing the Chinese market average. Despite this positive outlook, recent financial results show a decline in profit margins from 15.3% to 2.4%, and sales have decreased to CNY 1.74 billion in Q1 2025 from CNY 1.92 billion the previous year. The company's insider ownership remains high, but no significant insider trading activity was reported recently.

• Click here and access our complete growth analysis report to understand the dynamics of Lepu Medical Technology (Beijing).
• Insights from our recent valuation report point to the potential undervaluation of Lepu Medical Technology (Beijing) shares in the market.

Turning Ideas Into Actions

• Delve into our full catalog of 604 Fast Growing Asian Companies With High Insider Ownership here.
• Ready For A Different Approach? This technology could replace computers: discover the 26 stocks are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com